New Advances in High-Grade Glioma Research
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 1937
Special Issue Editors
Interests: brain tumors; glioma/glioblastoma; stem cells; pituitary adenoma; animal models; nerve surgery; neural regeneration; intraoperative neuromonitoring; intraoperative ultrasound
Interests: brain tumors; glioma/glioblastoma; stem cells; pituitary adenoma; animal models; nerve surgery; intraoperative neuromonitoring; intraoperative ultrasound
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
High-grade gliomas are the most frequent type of primary brain tumor. Notwithstanding their molecular heterogeneity, they share a dismal prognosis and resistance to currently available therapies. In recent years, huge advances have been made in glioma research. Surgery has become more refined, gaining the ability to reliably resect the bulk tumor without damaging healthy brain tissue. Radiotherapy has been revolutionized by technological innovation. Moreover, our understanding of the complex molecular mechanisms underlying gliomagenesis has greatly improved. These latter advances have led to the latest 2021 WHO classification of central nervous system tumors, in which molecular biology substantially contributes to the final, integrated diagnosis. In turn, the molecular sub-classification of gliomas has led to a better prediction of patient prognosis and has fostered a personalized approach to glioma treatment. However, this outbreak of knowledge on glioma has not translated to an improvement of patient outcome. Survival remains dismal in high-grade gliomas, not reaching 18 months in the most malignant histotype, namely, glioblastoma IDH-wildtype.
With this Special Issue, we plan to collect the most recent, innovative and ground-breaking research on high-grade glioma, encompassing surgical, clinical and bio-molecular advances. The final aim is to promote novel and effective treatments for this deadly disease. We thus welcome contributions from surgeons, radiation oncologists, neuro-oncologists, pathologists, molecular biologists, and all professionals involved in high-grade glioma research.
Prof. Dr. Liverana Lauretti
Dr. Quintino Giorgio D'Alessandris
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioma
- glioblastoma
- astrocytoma
- oligodendroglioma
- surgery
- radiotherapy
- chemotherapy
- molecular biology
- next-generation sequencing
- translational research
